FULL PRESCRIBING INFORMATION: CONTENTS*

1 HIGHLIGHTS OF PRESCRIBING INFORMATIONT hese highlights do not include all the information needed to use CIALIS safely and effectively. See full PRESCRIBING information for (tadalafil) tablets, for oral useInitial Approval: 2003---------------------------RECENT MAJOR CHANGES---------------------------Warnin gs and Precautions ( )05/2017----------------------------INDI CATIONS AND USAGE---------------------------CIALIS is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( ) ED and the signs and symptoms of BPH (ED/BPH) ( )If CIALIS isused with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks ( ).

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling Revised: 02/2018 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Erectile Dysfunction 1.2 Benign Prostatic Hyperplasia 1.3 Erectile Dysfunction and Benign Prostatic Hyperplasia 1.4 Limitation of Use 2 DOSAGE AND ADMINISTRATION

Loading..

Tags:

  Information, Patients, Approved, Labeling, Approved patient labeling

Information

Related search queries